"Zero deaths from melanoma"
Professor Georgina Long and Professor Richard Scolyer
Co-Medical Directors of Melanoma Institute Australia.
The details for this year’s lecture are as follows:
Date: Friday 9 August, 2019
Time: 5.30pm for 6.10pm start
Venue: Translational Research Institute (TRI) Auditorium, Brisbane
Professor Georgina Long, BSc PhD MBBS FRACP, is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases. In recognition of her ground breaking research, Professor Long has received a number of awards, including the prestigious Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research in 2016, and a number of recent CINSW Premiers Awards for Outstanding Cancer Research. She is President for the prestigious international Society for Melanoma Research (President from 2018), is member (2015-2017) and Chair (2016) of the ASCO Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.
Professor Richard Scolyer is Co-Medical Director and Consultant Pathologist at Melanoma Institute Australia; Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney; and Clinical Professor, The University of Sydney. Professor Scolyer studied medicine at the University of Tasmania. After completing clinical training in Australia and overseas, he undertook pathology training at the Canberra Hospital and at the Royal Prince Alfred Hospital leading to Fellowship of the Royal College of Pathologists of Australasia. He received a NSW Premier's Award for Outstanding Cancer Research in 2009, 2012, 2013, 2014, 2016, 2017 and the Thomson Reuters 2015 Citation Award in the Clinical Medicine category. He is also Vice Chair of the Melanoma Expert Panel of the American Joint Committee on Cancer (AJCC) for the 8th edition of the AJCC Cancer Staging System, Co-lead of the Australian Melanoma Genome Project, an editorial board member of the American Journal of Surgical Pathology, and a number of other international journals. Professor Scolyer is Immediate Past President of the Australasian Division of the International Academy of Pathology. Together with other MIA colleagues, Professor Scolyer is chief investigator on a 5-year NHMRC program grant and has a personal Fellowship from the NHMRC.
About Alan Cooper Epiderm Lecture
The Alan Cooper Epiderm Lecture has been established in recognition of Epiderm’s generous support of The University of Queensland’s dermatology and skin cancer research programs. Epiderm, formerly the Australian Dermatology Research and Education Foundation, was established in 1992 following Australia’s successful bid to host the International League of Dermatological Societies World Congress of Dermatology meeting in Sydney in 1997. The World Congress was led by Professor Alan Cooper and Professor Robin Marks and generated a significant financial surplus representing the majority of the Foundation’s initial funding.
Professor Alan Cooper, a driving force behind academic Dermatology in Australia, played a lead role on the board of Epiderm. Over a 22 year period, Epiderm funded many dermatological projects within Australia. From 2007-2014, Epiderm donated over $2.8 million in support of the dermatology and skin cancer research within the Dermatology Research Centre under the direction of Professor H. Peter Soyer. Epiderm’s capstone donation of $2.05 million in 2014, prior to the Foundations disestablishment, leveraged over $3.5 million in additional support for UQ’s dermatology and skin cancer research programs.